YOU SEARCHED BY...
SEARCH BY...
Contract Service Directory
Country
- Argentina(1)
- Australia(7)
- Austria(1)
- Belgium(3)
- Canada(53)
- China(20)
- Denmark(2)
- Finland(1)
- France(13)
- Germany(38)
- Greece(2)
- Hong Kong(1)
- Hungary(2)
- India(72)
- Ireland(2)
- Israel(3)
- Italia (5)
- Japan(2)
- Latvia(1)
- Mexico(2)
- New Zealand(1)
- Peru(1)
- Poland(1)
- Portugal(3)
- Romania(1)
- Singapore(1)
- Slovenia(2)
- South Korea(6)
- Spain(11)
- Sweden(3)
- Switzerland(23)
- Taiwan(3)
- The Czech Republic(1)
- The Netherlands(5)
- Turkey(2)
- Ukraine(1)
- United Kingdom(49)
- United States(646)
- Vietnam(1)
Contract Service Directory
Enteris BioPharma
Company Headquarters
83 Fulton St.
Boonton, NJ 07005
United States
Contract Service Directory
- 505(b)(2)
- Analytical Methods Development
- Drug Delivery Systems
- Feasibility Studies
- Filling, Capsule
- Formulation Development
- Formulation Services
- Formulation, Controlled Release
- Manufacturing, Cytotoxic & High Potency Compounds
- Manufacturing, Dose Form, Non-Sterile
- Manufacturing, Microbial-based Therapeutic Proteins
- Manufacturing, Nasal Delivery
- Manufacturing, Tablets
- Quality Control Testing
Content From Enteris BioPharma
-
HPAPI Drug Solid Oral Dosage (Sod) Manufacturing – Power, Precision and Productivity
How to Ensure Your CDMO Partner Has the Experience and Expertise to Get Your HPAPI Product Across the Finish Line.White Papers / Tech Papers Released on 10.27.2021
-
Analytical Services | APIs | cGMP Manufacture | Excipients | Formulation Development | QA/QC | R&D | Solid Dosage/Semi-solids
Enteris BioPharma: Custom Solutions – From Bench to Market
CDMO operations are housed within a 32,000-square-foot, FDA-inspected and cGMP-compliant facility in northern New Jersey.Sponsored Content Released on 04.01.2021
Related Content
-
Bio News | Breaking News | Clinical Trial Materials | Clinical Trials | Collaborations & Alliances | Drug Delivery | Industry News | Solid Dosage/Creams/Ointments
Enteris BioPharma Receives $10M Milestone from Cara Therapeutics
Third milestone payment related to the development of Oral KORSUVA.06.11.21
-
Bio News | Breaking News | cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Facilities | Industry News | Solid Dosage/Creams/Ointments
Enteris BioPharma Completes Expansion of Manufacturing Facility
Also launches CDMO business for the development and manufacture of difficult to formulate drugs and highly potent compounds.Tim Wright, Editor, Contract Pharma 05.11.21
-
Analytical Services | APIs | cGMP Manufacture | Excipients | Formulation Development | QA/QC | R&D | Solid Dosage/Semi-solids
Enteris BioPharma: Custom Solutions – From Bench to Market
CDMO operations are housed within a 32,000-square-foot, FDA-inspected and cGMP-compliant facility in northern New Jersey.
-
November 2019: Auction of Surplus Lab and Biotech Equipment from Enteris BioPharma
Don’t miss our upcoming auction featuring surplus lab and biotech equipment from a leading clinical stage biopharmaceutical CDMO.
-
Formulation Development | Industry News
Enteris, Cara Therapeutics Enter Peptelligence Pact
Cara has a non-exclusive, royalty-bearing license to the Peptelligence technology to develop, manufacture and commercialize Oral KORSUVA08.26.19
-
Breaking News | Collaborations & Alliances | Drug Development | Industry News
Ferring and Enteris Enter License Agreement
Will develop an oral formulation of a peptide-based injectable therapeutic02.01.17
-
Breaking News | Clinical Trial Materials | Collaborations & Alliances | Industry News | Solid Dosage/Creams/Ointments
Enteris to Develop Orally Delivered Metabolic Peptide
Enters agreement with Nordic Bioscience to lead the formulation and clinical manufacturing of Peptelligence-enabled compounds01.26.17
-
Drug Development | Promotions & Moves
-
Chemistry | Process Development | Regulatory Affairs
Differentiate By Being Specific
Why nimble niche CMOs may be a better choicePaul Shields and Angelo P. Consalvo, Enteris BioPharma 10.07.15
-
Drug Development | Process Validation | Validation
Specialization is a Key Value Add
CMOs, CDMOs and CROs are becoming more specialized to stand out in a hyper competitive marketTim Wright, Editor 10.07.15
-
APIs | Breaking News | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Industry News | Lyophilization | Process Development | Process Validation | Validation
Enteris BioPharma Launches Contract Manufacturing Ops
Will offer production of API using microbial expression systems02.27.15
-
Bioassay Development | Breaking News | Capsules | Drug Delivery | Drug Development | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Lyophilization | Methods Development | Process Development | Promotions & Moves | Solid Dosage/Semi-solids | Toxicology | Vials
-
Breaking News | Capsules | Drug Delivery | Formulation Development | Industry News | Promotions & Moves | Solid Dosage/Semi-solids | Vials
